Ciprofloxacin hydrochloride monohydrate
(Synonyms: 环丙沙星盐酸盐一水合物; Bay-09867 hydrochloride monohydrate) 目录号 : GC63671
A fluoroquinolone antibiotic
Cas No.:86393-32-0
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Ciprofloxacin is a fluoroquinolone antibiotic.1 It is active against a variety of Gram-positive and Gram-negative bacteria in vitro, including S. aureus, L. monocytogenes, P. aeruginosa, Legionella, N. gonorrhoeae, and H. pylori (MIC50s = 0.004-1 ?g/ml).2 It is also active against clinical isolates of Bacteroides, Fusobacterium, Eubacterium, Actinomyces, Peptococcus, Peptostreptococcus, and Streptococcus in vitro (MIC50s = 0.5-2 ?g/ml).3 Ciprofloxacin inhibits S. aureus DNA gyrase and topoisomerase IV (IC50s = 13.5 and 5.76 ?g/ml, respectively).4 It reduces mortality in mouse models of intraperitoneal E. coli, P. vulgaris, K. pneumoniae, P. aeruginosa, and S. aureus infection (ED90-100s = 1-5, 2.5-5, 5-10, 20-40, and 80 mg/kg, respectively) and prevents mortality in a mouse model of subcutaneous S. typhimurium infection at 10 mg/kg.5,6 Formulations containing ciprofloxacin have been used in the treatment of bacterial infections.
1.Drlica, K., and Zhao, X.DNA gyrase, topoisomerase IV, and the 4-quinolonesMicrobiol. Mol. Biol. Rev.61(3)377-392(1997) 2.Nilius, A.M., Shen, L.L., Hensey-Rudloff, D., et al.In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinoloneAntimicrob. Agents Chemother.47(10)3260-3269(2003) 3.Bansal, M.B., and Thadepalli, H.Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitroAntimicrob. Agents Chemother.31(4)619-621(1987) 4.Takei, M., Fukuda, H., Kishii, R., et al.Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibitionAntimicrob. Agents Chemother.45(12)3544-3547(2001) 5.Easmon, C.S.F., Crane, J.P., and Blowers, A.Effect of ciprofloxacin on intracellular organisms: In-vitro and in-vivo studiesJ. Antimicrob. Chemother.18 (Suppl D)43-48(1986) 6.Zeiler, H.J., and Grohe, K.The in vitro and in vivo activity of ciprofloxacinEur. J. Clin. Microbiol.3(4)339-343(1984)
Bacterial inocula are prepared by suspending colonies into Mueller-Hinton broth (CAMHB) (containing Ciprofloxacin (hydrochloride monohydrate)) from 18 to 24 h (B. anthracis) or 42 to 48 h (Y. pestis) on sheep blood agar (SBA) plates that are incubated at 35°C. Suspended cultures are diluted with CAMHB to a bacterial cell density of 105 CFU/mL adjusted based on the optical density at 600 nm. To each well of the 96-well plate, 50 μL of dilutions is added for a final inoculum of ~5×104 CFU/well. Plates are incubated at 35°C. MICs are determined visually at 18 to 24 h (B. anthracis) or 42 to 48 h (Y. pestis) and also by absorbance at 600 nm[2].
Female BALB/cAnNCrl (BALB/c) mice, 8 to 10 weeks old and 20 g (±4 g) are used in this assay. A single dose of Ciprofloxacin (hydrochloride monohydrate) (30 mg/kg) is administered to mice (n=30) via the intraperitoneal (i.p.) route. The mice (n=3/time point/group) are culled at 1, 10, 20, or 30 min and 1, 1.5, 2, 4, 8, 12 h following Ciprofloxacin (hydrochloride monohydrate) administration and 1, 15, or 30 min and 1, 2, 4, 6, 10, 18, or 24 h following DRCFI or CFI administration. Blood sampling points are chosen based upon the short half-life of Ciprofloxacin (hydrochloride monohydrate) and longer half-life of CFI. Blood and lungs (whole organ) are collected post mortem for analysis. The lung doses following CFI or DRCFI administration are calculated using the concentration of Ciprofloxacin (hydrochloride monohydrate) in the lung samples at 1 min post-administration[3].
[1]. Peltzer PM, et al. Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae. Environ Toxicol Pharmacol. 2017 Feb 4. pii: S1382-6689(17)30029-7.
[2]. Steenbergen J, et al. In Vitro and In Vivo Activity of Omadacycline Against Two Biothreat Pathogens: Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Feb 21.
[3]. Hamblin KA, et al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.
| Cas No. | 86393-32-0 | SDF | |
| 别名 | 环丙沙星盐酸盐一水合物; Bay-09867 hydrochloride monohydrate | ||
| 分子式 | C17H21ClFN3O4 | 分子量 | 385.82 |
| 溶解度 | DMSO : 5 mg/mL (12.96 mM） | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5919 mL | 12.9594 mL | 25.9188 mL |
| 5 mM | 0.5184 mL | 2.5919 mL | 5.1838 mL |
| 10 mM | 0.2592 mL | 1.2959 mL | 2.5919 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet